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Abstract: Macular edema is one of the leading causes of vision loss among patients with retinal 
vein occlusion, diabetic retinopathy, and posterior chamber inflammatory disease. However, 
the treatment of macular edema is considerably limited by the difficulty in delivering effective 
doses of therapeutic agents into the vitreous cavity. In recent years, the development of a 
sustained-release dexamethasone intravitreal implant (Ozurdex®) has enabled more controlled 
drug release at a stable rate over a long period of time, with a potentially lower rate of adverse 
events. Clinical studies indicate that this dexamethasone implant is a promising new treatment 
option for patients with persistent macular edema resulting from retinal vein occlusion, diabetic 
retinopathy, and uveitis or Irvine-Gass syndrome.
Keywords: diabetic retinopathy, macular edema, Ozurdex®, posterior-segment inflammatory 
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Introduction
Macular edema is thought to be due to abnormal retinal capillary permeability, 
  manifesting by extravascular swelling in the macula.1 Macular edema is associated with 
a variety of underlying diseases, but is most commonly seen in patients with retinal 
venous occlusion, diabetic retinopathy, and posterior-segment   inflammatory disease.1–3 
Current evidence suggests that the pathological processes leading to macular edema 
involve numerous inflammatory cells, cytokines, growth factors, and intercellular 
  adhesion molecules, which are associated with increased vascular permeability, 
breakdown of the blood–retinal barrier, remodeling of the extracellular matrix, and 
upregulation of proangiogenic factors.4–8
Macular edema is one of the leading causes of vision loss among patients with   retinal 
vein occlusion, diabetic retinopathy, and posterior-segment inflammatory disease. 
However, the treatment of macular edema is considerably limited by the difficulty in 
delivering effective doses of therapeutic agents into the vitreous cavity. While various 
therapeutic agents, such as antivascular endothelial growth factor, along with an array 
of technologies to circumvent the blood–retinal barrier are under development,9–12 
a sustained-release dexamethasone implant has recently become available for the 
  treatment of macular edema secondary to a variety of underlying diseases.
Treatment of macular edema
Traditionally, the main treatment options for macular edema are laser photocoagulation 
and anti-inflammatory therapy depending on etiology. Laser photocoagulation   prevents Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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further vision loss in patients with macular edema caused 
by diabetes and retinal vein occlusion.13–15 However, the 
prevention of visual decline is not always uniform, and some 
patients can be refractory to laser treatment. In addition, this 
mode of therapy is associated with moderate visual loss, a 
diminished visual field, and reduced color vision and contrast 
sensitivity.16–18
Corticosteroids are potent anti-inflammatory agents 
that can counteract many of the pathological processes 
thought to play a role in the development of macular edema. 
  Corticosteroids prevent leukocyte migration, reduce fibrin 
deposition, stabilize endothelial cell tight junctions, and 
inhibit synthesis of vascular endothelial growth factor, 
  prostaglandins, and proinflammatory cytokines.19 However, 
the route of corticosteroid administration dramatically affects 
the risk to benefit ratio of corticosteroid therapy (Table 1). 
Oral corticosteroids are complicated with many adverse 
events, including osteoporosis, a Cushingoid state, adrenal 
suppression, and exacerbation of diabetes.20–23 Topical, 
peribulbar, and subconjunctival corticosteroid administrations 
deliver suboptimal vitreous drug levels (Table 1) with a very 
short half-life (approximately 3.5 hours) and are associated 
with relatively high systemic corticosteroid   concentrations, 
which can potentially be accompanied by significant adverse 
events.24–28 On the other hand, direct intravitreal   corticosteroid 
administration bypasses the blood–retinal barrier, leading 
to high local drug concentrations with no or little systemic 
adverse events.
Given the short half-life of dexamethasone in the vitre-
ous cavity, the crystalline form of a lipophilic corticosteroid, 
triamcinolone acetonide (Kenalog®-40, Bristol-Myers 
Squibb, Princeton, NJ), with a vitreous residence time of 
several months, gained widespread use for treatment of 
macular edema secondary to retinal vein occlusion, diabetic 
retinopathy, and uveitis, in spite of the lack of controlled, 
randomized studies demonstrating that its efficacy exceeds 
the risks.29–33 Recent randomized trials demonstrated that 
intravitreal triamcinolone acetonide was more effective 
than observation in patients with macular edema   secondary 
to   central retinal vein occlusion, and as effective as 
laser therapy in patients with macular edema   secondary to 
branch retinal vein   occlusion in   improving visual acuity.34,35 
In diabetic patients with macular edema, laser therapy was 
more effective than intravitreal   triamcinolone acetonide in 
improving visual acuity at the study primary endpoint of 
two years, although triamcinolone acetonide was initially 
more effective than laser at four months.36 However, in 
those studies, intravitreal triamcinolone acetonide was 
associated with a high rate of elevated intraocular pressure 
and   cataract formation, two ocular adverse events that have 
been linked most commonly to corticosteroid therapy.37–39 
The incidence of a $10 mmHg increase in intraocular 
pressure from   baseline ranged from 24% to 50% in the 
intravitreal   triamcinolone acetonide 4 mg group com-
pared with 2% to 13% in the observation or laser therapy 
group.34–36 The incidence of cataract surgery ranged from 
23% to 51% in the intravitreal triamcinolone acetonide 
4 mg group   compared with 0% to 13% in the observation 
or laser therapy group.
In recent years, the development of a sustained-release 
intravitreal dexamethasone implant (Ozurdex®, Allergan Inc, 
Irvine, CA) enabled more controlled delivery of drug, with a 
potentially lower rate of adverse events. The dexamethasone 
implant is now emerging as a potential treatment for 
macular edema arising from retinal vein occlusion, diabetic 
  retinopathy, and uveitis.
Sustained-release  
dexamethasone implant
Among the corticosteroids, dexamethasone is one of the most 
potent, with an anti-inflammatory activity that is six-fold 
greater than that of triamcinolone and 30-fold greater than 
cortisol.40 In the dexamethasone implant, the active drug 
is dispersed through a biodegradable copolymer of lactic 
acid and glycolic acid (PLGA), forming a matrix structure 
(Novadur™, Allergan Inc).41 These polymers have been used 
in a number of products, including absorbable sutures.42,43 For 
several years, PLGA has been used to prepare nanoparticles 
and microparticles for intraocular drug delivery. These drug 
delivery systems have been tested in animal models and 
humans.44–47
In the early clinical studies, the dexamethasone implant 
was surgically implanted into the vitreous cavity via a pars 
plana incision.48–50 Subsequently, a single-use, sutureless 
dexamethasone posterior-segment drug delivery system 
(DDS) applicator was developed, allowing injection of the 
Table 1 Traditional routes of dexamethasone administration pro-
vide suboptimal vitreous levels and high systemic concentrations
Route Dose (mg) Vitreous Cmax  
(ng/mL)
Serum Cmax   
(ng/mL)
Oral 7.5 5.2 61.6
Topical 0.5a 1.1 0.7
Peribulbar 3.8 13 60
Subconjunctival 1.9 72.5 32.4
Note: a10–11 drops from 0.1% dexamethasone solution every hour. 
Abbreviation: Cmax, maximum concentration.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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dexamethasone implant in the office rather than in a   surgical 
setting (Figure 1).51 The dexamethasone implant was observed 
for six months after implantation in monkey eyes.52 The 
dexamethasone implant releases the drug by diffusion in 
a biphasic fashion, with higher doses for up to six weeks 
followed by lower doses for up to six months (Figure 2).52 
Experience has shown that PLGA is biocompatible and, inside 
the eye, is metabolized into carbon dioxide and water. Thus, 
sequential implants can be placed in an office setting without 
the need for surgical removal. The dexamethasone implant is 
indicated for the treatment of macular edema   following retinal 
vein occlusion.41 The safety and efficacy of the dexamethasone 
implant have also been investigated in uveitic, diabetic, and 
vitrectomized diabetic patients with macular edema.
Phase ii studies
A Phase II trial evaluated the safety and efficacy of the 
dexamethasone implant in patients with persistent macular 
edema.49 This study enrolled patients $12 years of age with 
a best-corrected visual acuity (BCVA) of 20/40 to 20/200 
because of clinically detectable macular edema persisting 
for $90 days after laser or medical therapy. Macular edema 
was secondary to central retinal vein   occlusion, branch retinal 
vein occlusion, diabetic retinopathy, uveitis, or   Irvine-Gass 
syndrome. A total of 315 patients were   randomized in a 
1:1:1 ratio to observation or to treatment with a surgically 
placed dexamethasone implant at two doses, ie, 0.35 mg or 
0.7 mg. The primary outcome measure was the proportion 
of patients who achieved at least a 10-letter improvement in 
BCVA at day 90.49
The proportion of patients with a $10-letter or $15-letter 
improvement in BCVA at day 90 was significantly higher 
in the 0.7 mg dexamethasone implant group compared with 
the observation group. At day 180, a significantly greater 
proportion of patients treated with the 0.7 mg dexamethasone 
implant achieved a $10-letter or $15-letter improvement 
in BCVA (Figure 3). There were no statistically significant 
differences in improvement of BCVA between the 0.35 mg 
dexamethasone implant group and the observation group 
at day 90 or 180.49 Treatment with dexamethasone implant 
at either dose (0.35 mg or 0.7 mg) significantly decreased 
central retinal thickness and fluorescein angiographic leakage 
at day 90 compared with the observation group.49
In the Phase II study, the dexamethasone implant was well 
tolerated and had a favorable safety profile. The incidence of 
a $10 mmHg increase in intraocular pressure from baseline 
was 3% in the observation group, 12% in the 0.35 mg 
  dexamethasone implant group, and 17% in the 0.7 mg dexam-
ethasone implant group. Most of these patients (.65%) had 
only a single occurrence of an intraocular pressure increase 
of this magnitude or greater. No significant between-group 
differences were found in the number of reports of cataract. 
However, treatment-related cataract formation may take 
longer than 180 days to become apparent.49
Implant
Macula
Applicator
A
B
Figure 1 Dexamethasone Posterior Segment Drug Delivery System® Applicator   
and approximate vitreous location of dexamethasone implant after insertion. The 
implant is approximately 6 mm long and is inserted into the vitreous cavity through 
the 22-gauge needle of the applicator.
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Figure  2  Temporal  kinetics  of  dexamethasone  concentrations  in  the  vitreous 
cavity, retina, and plasma following placement of the 0.7 mg dexamethasone implant 
in monkeys. The dexamethasone concentration was below the minimum detection 
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In the Phase II study, subset analyses were performed 
to evaluate whether the treatment effect was similar across 
the underlying causes of persistent macular edema. These 
analyses showed that the improvement in BCVA at day 90 
was more favorable in the 0.7 mg dexamethasone implant 
group than in the observation group, regardless of the 
underlying cause of macular edema (Figure 4).48–50 In a   subset 
of patients with retinal vein occlusion, an improvement in 
BCVA of $10 letters at day 90 was observed in 31% of 
patients treated with the 0.7 mg dexamethasone implant 
compared with 15% of patients in the observation group.49 
In a subset of patients with uveitis or Irvine-Gass   syndrome, 
an improvement in BCVA of $10 letters at day 90 was 
observed in 53.8% of patients treated with the 0.7 mg 
  dexamethasone implant compared with 14.3% of patients in 
the   observation group.50 In a subset of patients with diabetic 
macular edema, an improvement in BCVA of $10 letters 
at day 90 was observed in 33.3% of patients treated with 
the 0.7 mg dexamethasone implant compared with 12.3% 
of patients in the observation group.48 Among diabetic 
patients, this significant difference was maintained when 
patients were stratified according to their pattern of diabetic 
macular edema, ie, focal, diffuse, cystoid, and both cystoid 
and diffuse.53 Overall, the pattern of adverse events seen in 
these subpopulations was similar to that seen in the overall 
population of patients included in the Phase II study.48–50
Phase iii studies
Two identical, multicenter, masked, randomized, clinical 
trials evaluated the safety and efficacy of the dexamethasone 
implant as compared with sham in eyes with vision loss due 
to clinically detectable macular edema associated with either 
central or branch retinal vein occlusion.54 A total of 1267 
patients was randomized in a 1:1:1 ratio to either a sham 
procedure or treatment with the dexamethasone implant at 
the dose of 0.35 mg or 0.7 mg. The dexamethasone implant 
was inserted into the vitreous cavity through the pars plana 
by a single-use DDS applicator. The primary efficacy 
  outcome for the pooled data from the two Phase III studies 
was the time to reach a 15-letter improvement from baseline 
BCVA.54
Eyes receiving dexamethasone implants achieved a 
15-letter improvement in BCVA significantly faster than did 
eyes receiving sham treatment (Figure 5).54 The   proportion 
of eyes achieving at least a 15-letter improvement from 
  baseline BCVA was significantly greater in both dexametha-
sone implant groups than in the sham group from day 30 
through day 90, with the greatest response (29%) at day 60 
(P , 0.001).54 The mean increase from baseline visual acuity 
was also significantly greater in both dexamethasone implant 
groups than in the sham group from day 30 through day 
180 (P # 0.006, Figure 6), with the greatest between-group 
difference (approximately 10 letters) at day 60.54 The mean 
decrease in central retinal thickness was significantly greater 
in both dexamethasone implant groups compared with the 
sham group at day 90 (P , 0.001) but not at day 180.54
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In a prospectively defined subgroup analysis, the key 
efficacy outcomes (time to 15-letter improvement, proportion 
of eyes achieving at least a 15-letter improvement, and mean 
change from baseline BCVA) were evaluated for the branch 
and central retinal vein occlusion populations separately. In 
general, the response to the dexamethasone implant in both 
subgroups was qualitatively similar to the response seen in 
the overall population, but the response in the sham group 
was greater in the branch retinal vein occlusion subgroup 
than in the central retinal vein occlusion subgroup in all 
efficacy analyses. The difference between the sham groups 
was particularly marked in the analysis of mean change from 
baseline BCVA (Figure 7). These findings support previous 
observations that central retinal vein occlusion is a more 
visually disabling disorder than branch retinal vein occlusion. 
Eyes with central retinal vein occlusion did not respond as 
well to therapy as eyes with branch retinal vein occlusion, 
and they were not improved without therapy.54
In the Phase III study, a post hoc subgroup analysis based 
on the duration of macular edema at baseline found that the 
response to the dexamethasone implant (proportion of eyes 
improving by $15 letters and mean change from baseline 
BCVA) was often greater among eyes with a shorter duration of 
macular edema at baseline (#90 days) as compared with a lon-
ger duration (.90 days) of macular edema.54 A similar effect of 
macular edema duration was seen in SCORE (Standard Care 
versus cOrticosteroid for REtinal vein occlusion study).34,54
In the Phase III study, the dexamethasone implant was 
well tolerated and associated with generally transient, 
moderate, and readily manageable adverse events. Those 
adverse events that occurred significantly more frequently 
in either dexamethasone implant group than in the sham 
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group were eye pain (P = 0.023), anterior chamber cells 
(P # 0.031), and ocular hypertension (P # 0.002).54 The 
percentage of eyes receiving intraocular pressure-lowering 
medication increased in the dexamethasone implant groups 
from approximately 6% at baseline to 24% at day 180, while 
there was no change in the sham group. Overall, the propor-
tion of patients experiencing an intraocular pressure elevation 
of $10 mmHg from baseline peaked at day 60, and was less 
than 1% in the sham group and approximately 15% in both 
dexamethasone implant groups.54 There was no statistically 
significant difference between the treatment groups in the 
incidence of cataract.54 As with the Phase II studies, 180 days 
may not be long enough for detection of treatment-related 
cataract formation.
Recent studies for other indications
Recent clinical studies have evaluated the safety and efficacy 
of the dexamethasone implant as monotherapy for uveitic 
and diabetic macular edema. The efficacy of the dexametha-
sone implant in vitrectomized eyes is of particular interest 
because preclinical studies show that after implantation, 
vitreous and retinal dexamethasone concentrations in 
  vitrectomized eyes are similar to those in nonvitrectomized 
eyes.55 The dexamethasone implant was also investigated 
as a combination therapy with laser   photocoagulation in 
diabetic macular edema patients and with ranibizumab 
(Lucentis®, Genentech Inc, San Francisco, CA) in patients 
with   choroidal neovascularization secondary to exudative 
age-related macular degeneration. The findings of these 
studies   indicate that the dexamethasone implant   significantly 
improves intraocular inflammation and visual acuity in 
uveitic macular edema patients, increases visual acuity in 
a difficult-to-treat vitrectomized population with chronic 
diabetic macular edema, and reduces the need for repeated 
ranibizumab injections in patients with choroidal neovas-
cularization secondary to exudative age-related macular 
degeneration.55
Conclusion
Phase II and III studies indicate that the 0.7 mg dexamethasone 
implant is consistently more efficacious than the 0.35 mg 
dexamethasone implant. The response to treatment with 
the 0.7 mg dexamethasone implant lasts for up to 180 days. 
Further studies are warranted to determine the response to 
repeated treatments, as well as the optimum retreatment 
interval in patients who require a longer duration of 
treatment. Nevertheless, clinical studies demonstrate that 
the   dexamethasone implant is a promising new treatment 
option for patients with persistent macular edema resulting 
from retinal vein occlusion, diabetic retinopathy, and uveitis 
or Irvine-Gass syndrome.48–50,54 Further studies are warranted 
to support the clinical value of the dexamethasone implant 
in these patient populations.
Given the differences in patient populations, efficacy 
endpoints, and reporting of adverse events, it is not pos-
sible to compare directly the findings of the dexamethasone 
implant trials with those of the intravitreal triamcinolone 
acetonide trials. Head-to-head clinical studies are   warranted 
to compare the safety and efficacy of the dexamethasone 
implant with those of intravitreal triamcinolone acetonide in 
macular edema patients. Mathematical models   predict that 
placement of the dexamethasone implant in a more posterior 
vitreous location than the current anterior   vitreous location 
maximizes macular drug exposure while   minimizing   anterior 
chamber drug exposure. Such a change in anatomical 
localization of the dexamethasone implant may further 
decrease the incidence of intraocular pressure elevation.56
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